Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation

被引:29
|
作者
Majeau, GR [1 ]
Whitty, A [1 ]
Yim, K [1 ]
Meier, W [1 ]
Hochman, PS [1 ]
机构
[1] Biogen Inc, Cambridge, MA 02142 USA
关键词
CD2; LFA-3; CD58; affinity; avidity; cell adhesion;
D O I
10.3109/15419069909010808
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Quantitative analysis of binding of the bivalent recombinant soluble fusion protein, LFA3/IgG1, shows that the fusion protein binds to human CD2(+) PBLs primarily through low affinity (K-D similar to 140 mu M) but also through high avidity (90 nM) interactions. The concentration dependence for LFA-3/IgG1 PBL binding took: the form of two overlapping bell-shaped curves separated by a clear and reproducible minimum. This was accounted for in part by minor heterogeneity in the LFA-3/IgG1 preparations, and potentially by the ability of the ligand to bind to both CD2 and Fc receptors (FcR), best evidenced by the distinct binding properties of the fusion protein to NK and T cells. The low affinity LFA-3/ IgG1 binding to T cells is consistent with binding to CD2 only, and is in agreement with the low affinity reported for interactions between soluble forms of LFA-3 and CD2 by surface plasmon resonance technology. Moreover, as the low affinity determinations are similar for CD2 on resting and activated T cells, although the CD2 molecule has been reported to be altered to reveal new epitopes upon T cell activation, the binding data argue against multiple cell activation-dependent affinity states of CD2 for LFA-3 binding. This is distinct from that observed with other adhesion partners, and suggests that the different adhesion pathways utilize distinct mechanisms to mediate cell adhesion.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 50 条
  • [2] Selective T cell reduction in scleroderma lung disease, using LFA-3/IgG1 human fusion protein (Alefacept).
    White, B
    Choi, J
    Wigley, F
    Wise, R
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S202 - S202
  • [3] Alefacept (LFA-3/IgG1), a fully human fusion protein, is non-immunogenic
    Christophers, E
    Krueger, G
    Rizova, E
    Griffiths, CEM
    ALLERGY, 2002, 57 : 61 - 61
  • [4] T-CELL ACTIVATION BY LFA-3 AND CD2 ANTIBODIES
    DUSTIN, ML
    OLIVE, D
    SPRINGER, TA
    FASEB JOURNAL, 1988, 2 (05): : A1239 - A1239
  • [5] Targeting CD2 for immunotherapy: Results of a phase 1 trial with a LFA-3/IgG Fc fusion protein.
    Magilavy, D
    Norman, P
    Majeau, G
    Knox, S
    Winkler, G
    MacLellan, S
    Sartori, L
    Rogge, M
    Cooney, M
    Meier, W
    Hochman, P
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 873 - 873
  • [6] Targeting CD2 for immunotherapy: Results of a phase 1 trial with a LFA-3/IgG Fe fusion protein.
    Magilavy, D
    Norman, P
    Majeau, G
    Knox, S
    Winkler, G
    MacLellan, S
    Sartori, L
    Cooney, M
    Meier, W
    Hochman, P
    Rogge, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 682 - 682
  • [7] Cognate interactions mediated by a recombinant LFA-3/IgG1 fusion induce CD16 signaling and granzyme B dependent apoptosis of activated CD2+cells.
    da Silva, AJ
    Brickelmaier, M
    Majeau, G
    Li, ZF
    Hochman, P
    JOURNAL OF LEUKOCYTE BIOLOGY, 2001, : 55 - 55
  • [8] Alefacept (LFA-3/IgG1) selectively targets CD45RO+ T cells, producing durable improvements in psoriasis and psoriatic arthritis
    Krueger, GG
    Lebwohl, M
    Griffiths, CEM
    Dinant, HJ
    Goedkoop, AY
    ALLERGY, 2002, 57 : 61 - 62
  • [9] HUMAN CYTOTOXIC T-CELLS ADHERE TO POTENTIAL TARGETS BY 2 ANTIGEN-INDEPENDENT PATHWAYS - CD2 BINDING TO LFA-3 OR LFA-1 BINDING TO AN UNDEFINED LIGAND
    SHAW, S
    LUCE, GG
    SPRINGER, TA
    PLUNKETT, ML
    QUINONES, R
    GRESS, RE
    SANDERS, ME
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 207 - 207
  • [10] Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept
    Larsen, R.
    Ryder, L. P.
    Svejgaard, A.
    Gniadecki, R.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 149 (01): : 23 - 30